Crown Bioscience and The Jackson Laboratory Collaboration Enables Global Access to FATZO Mouse Model
Continued Collaboration Facilitates Global Distribution of Obesity, Metabolic Disease, and NASH Model and Priority Supply to CrownBio’s World-Class Cardiovascular, Obesity, and Metabolic Disease Platform
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced an exclusive agreement with The Jackson Laboratory (JAX)
to utilize its world-class distribution channels to make the FATZO mouse model available to researchers globally.
As CrownBio’s exclusive distributor of the FATZO model, JAX, the independent, nonprofit biomedical research organization will utilize its expertise in the breeding, production, and delivery of high-quality mouse models to increase worldwide access with immediate effect. As part of the agreement, JAX will provide a prioritized model supply to support CrownBio’s global service platform in obesity, diabetes and associated indications.
A unique and proprietary model to CrownBio, the FATZO model, is a translationally-relevant, inbred polygenic mouse model ideal for the study of obesity, metabolic syndrome and diabetes, and drug development. The model is sensitive to developing obesity and metabolic syndrome under the influence of a high-fat diet, which has been demonstrated to be a significant factor in the human development of these conditions. The model also exhibits human-like disease progression, making it an ideal candidate for modeling human metabolic syndrome.
“I am excited that our ongoing relationship with The Jackson Laboratory has resulted in this agreement and will enable easier access to FATZO, thereby accelerating discovery in obesity, diabetes, and NAFLD/NASH,” said Dr. Jim Wang, senior vice president of CrownBio’s Cardiovascular and Metabolic Disease division.
To learn more about the FATZO mouse and Crown’s Cardiovascular and Metabolic Disease platform, visit: www.crownbio.com/cvmd
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc.
The Jackson Laboratory
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
Abeona Therapeutics Inc.21.5.2019 14:03:09 CEST | Pressemeddelelse
Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
Invivoscribe, Inc.21.5.2019 12:02:33 CEST | Pressemeddelelse
Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies
GridGain Systems21.5.2019 09:02:54 CEST | Pressemeddelelse
GridGain Joins Cloud Native Computing Foundation
IMImobile21.5.2019 09:02:54 CEST | Pressemeddelelse
Telia Norway signs partner agreement with IMImobile for Enterprise cPaaS offering
Worksoft20.5.2019 17:56:04 CEST | Pressemeddelelse
Deutsche Telecom to Showcase How Intelligent Automation is Driving Quality and Program Efficiencies for ERP Transformation
Merus N.V.20.5.2019 14:41:11 CEST | Pressemeddelelse
Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum